Sign in
TerminatedPhase 3

Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 3
People taking part
217 people enrolled
Started
18 Aug 2017
Ended
16 May 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Diet
Record updated
7 April 2025
Why it stopped
Interim analysis determined that study reached a safety stopping rule

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age 18 years or older
  • Undergoing treatment for hematologic malignancies or HSCT as outlined below:
  • Underlying diagnosis for non-HSCT patients:
  • Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving induction or reinduction chemotherapy; OR
  • Acute lymphoblastic leukemia (ALL) receiving an intensive induction chemotherapy (e.g., HyperCVAD±R, CALGB9251, Larsons protocol) with an expected duration of neutropenia of ≥7 days; OR
  • Allogeneic or autologous HSCT for any indication. For patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is ≥ 7 days are permitted and the patient must reside in the hospital
  • Expected duration of neutropenia of ≥ 7 days

Who cannot take part

  • Use of anti infectives for treatment of active systemic infections within 7 days prior to initiation of study diet
  • Untreated major infection at presentation
  • Patients with uncontrolled invasive fungal infection (defined as those who have not completed at least 6 weeks of treatment; or who are symptomatic with two CT scans, at least 1 week apart showing uncontrolled disease at the time of initiation of study diet)
  • Uncontrolled HIV, Hepatitis B and C infection
  • Receipt of nutrition via enteral tube or total parenteral nutrition at the time of enrollment
  • Patients unwilling to eat fresh fruit and/or vegetables
  • Planned management of neutropenia in the outpatient setting

Where in United States

  • UF Health Cancer CenterGainesville, United States

About the trial

What the trial wants to find out

This is an open-label, two-arm, phase III non-inferiority trial to evaluate the safety of a liberalized hospital diet inclusive of fresh fruits and vegetables to a neutropenic diet in patients with prolonged neutropenia. Both cohorts and diets will adhere to the hygiene and common sense advice listed in the FDA-endorsed food safety guidelines.

The 2 groups in the trial

  • Liberalized Hospital Diet (Diet A)Existing treatment, for comparison

    Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.

    Treatment: Diet

  • Neutropenic Diet (Diet B)Existing treatment, for comparison

    Diet B is the hospital neutropenic diet.

    Treatment: Diet

Results explained

A paper that names this trial, explained in plain words.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Randomized, Clinical Trial Comparing Two Diets in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia and Myelodysplastic Syndrome (UF-BMT-LDND-101)
Publications
Record updated
7 April 2025